FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
FDA approves Roche’s $90,000 lymphoma combinationThe FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – Share XFDA approves Roche’s $90,000 lymphoma combinationhttps://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/
AstraZeneca ends another Calquence trial earlyFor the second time in the space of a month AstraZeneca has stopped a trial of its chronic Share XAstraZeneca ends another Calquence trial earlyhttps://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/
Relax criteria to increase sign-ups to cancer trials, says ASCOOnly 3% of patients with cancer in the US enrol on a clinical trial – and the American Share XRelax criteria to increase sign-ups to cancer trials, says ASCOhttps://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Sanofi trumpets Darzalex rival isatuximab in refractory myelomaSanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share XSanofi trumpets Darzalex rival isatuximab in refractory myelomahttps://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
MacroGenics looks to future with breast cancer drug margetuximabA small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its Share XMacroGenics looks to future with breast cancer drug margetuximabhttps://pharmaphorum.com/news/macrogenics-looks-to-future-with-breast-cancer-drug-margetuximab/
